Ultrasensitive flow-based immunoassays using single-molecule counting
Ultrasensitive flow-based immunoassays using single-molecule counting
复制标题
DOI：
10.1373/clinchem.2007.091181
复制
发表时间：
2007-11-01
影响因子：
9.3
通讯作者：
Goix, Philippe
中科院分区：
文献类型：
--
作者：
Todd, John;Freese, Bob;Goix, Philippe
背景：免疫测定（IA）技术扩大了蛋白质生物标志物的临床用途，但对提高灵敏度、动态报告范围和小样本量的需求限制了许多生物标志物的潜在临床用途。我们评估了基于 IA 的技术 Erenna 免疫分析系统对一系列生物标志物（包括心肌肌钙蛋白 I (cTnI)）的性能，包括检测限 (LOD) 和动态报告范围。方法：Erenna IAs 与 10 种不同的临床重要生物标志物一起使用，以确定不同样本量（10 μL 至 200 μL）的 LOD。结果：Erenna 免疫分析系统生成 LOD使用 100 μL 样品，浓度为 10-100 pg/L。对于 cTnI，LOD 为 0.2 ng/L，在 0.78 和 1.6 ng/L 之间观察到 10% CV。结论：基于 Erenna IA 的技术可重复测量蛋白质生物标志物，检测限为 10-100 pg/L，在 50-150 μL 样本量中动态范围 >4.5 个对数。 (C) 2007 年美国临床协会化学。
Background: Immunoassay (IA) technology has expanded the clinical utility of protein biomarkers, but demands for increased sensitivity, dynamic reporting ranges, and small sample volumes have limited the potential clinical usefulness of many biomarkers. We assessed the performance, including limits of detection (LODs) and the dynamic reporting range, of an IA-based technology, Erenna Immunoassay System, for a series of biomarkers, including cardiac troponin I (cTnI).Methods: Erenna IAs were used with 10 different and clinically important biomarkers to ascertain the LOD with various sample sizes (10 mu L to 200 mu L).Results: The Erenna Immunoassay System generated LODs of 10-100 pg/L using 100 mu L of sample. For cTnI, the LOD was 0.2 ng/L and a 10% CV was seen between 0.78 and 1.6 ng/L.Conclusions: The Erenna IA-based technology reproducibly measures protein biomarkers with detection limits of 10-100 pg/L, with a dynamic range of >4.5 logs in sample volumes of 50-150 mu L. (C) 2007 American Association for Clinical Chemistry.